Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer‐cell malignancies

BCX1777 (forodesine), a novel purine nucleoside phosphorylase inhibitor, induces apoptosis, mainly in T cells. To evaluate the safety, tolerability, and pharmacokinetics of BCX1777, we conducted a phase I study in patients with relapsed or refractory peripheral T/natural killer‐cell malignancies. El...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Sci
Huvudupphovsmän: Ogura, Michinori, Tsukasaki, Kunihiro, Nagai, Hirokazu, Uchida, Toshiki, Oyama, Takashi, Suzuki, Tatsuya, Taguchi, Jun, Maruyama, Dai, Hotta, Tomomitsu, Tobinai, Kensei
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2012
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659180/
https://ncbi.nlm.nih.gov/pubmed/22448814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02287.x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk